Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
Sales | 11,865,000 | 11,477,000 | 10,966,000 | 11,226,000 | 11,337,000 |
Cost of Goods | 2,932,000 | 2,745,000 | 2,506,000 | 2,876,000 | 2,566,000 |
Gross Profit | 8,933,000 | 8,732,000 | 8,460,000 | 8,350,000 | 8,771,000 |
Operating Expenses | 20,449,000 | 7,058,000 | 6,323,000 | 6,491,000 | 6,001,000 |
Operating Income | -11,516,000 | 1,674,000 | 2,137,000 | 1,859,000 | 2,770,000 |
Pre-tax Income | -11,516,000 | 1,674,000 | 2,137,000 | 1,859,000 | 2,770,000 |
Income Tax | 392,000 | -88,000 | 203,000 | -218,000 | 503,000 |
Net Income Continuous | -11,908,000 | 1,762,000 | 1,934,000 | 2,077,000 | 2,267,000 |
Minority Interests | 3,000 | N/A | 6,000 | 4,000 | 5,000 |
Net Income | $-11,911,000 | $1,762,000 | $1,928,000 | $2,073,000 | $2,262,000 |
EPS Basic Total Ops | -5.89 | 0.87 | 0.94 | 0.99 | 1.08 |
EPS Basic Continuous Ops | -5.89 | 0.87 | 0.94 | 0.99 | 1.08 |
EPS Diluted Total Ops | -5.89 | 0.87 | 0.93 | 0.99 | 1.07 |
EPS Diluted Continuous Ops | -5.89 | 0.87 | 0.94 | 0.99 | 1.07 |
EPS Diluted Before Non-Recurring Items | -4.40 | 1.70 | 2.00 | 1.75 | 2.05 |
EBITDA(a) | $-8,984,000 | $4,138,000 | $4,572,000 | $4,291,000 | $5,199,000 |